Table 3. Correlation between KRAS overexpression and KRAS mutation in CTC.
| KRAS overexpression CTC | Total | ||||
|---|---|---|---|---|---|
| Negative | Positive | ||||
| KRAS overexpression CTC | Negative | Count | 12 | 6 | 18 |
| % within KRAS overexpression CTC | 66.7% | 33.3% | 100.0% | ||
| % within K-RAS CTC | 48.0% | 85.7% | 56.2% | ||
| % of total | 37.5% | 18.8% | 56.2% | ||
| Positive | Count | 13 | 1 | 14 | |
| % within KRAS overexpression CTC | 92.9% | 7.1% | 100.0% | ||
| % within KRAS CTC | 52.0% | 14.3% | 43.8% | ||
| % of total | 40.6% | 3.1% | 43.8% | ||
| Total | Count | 25 | 7 | 32 | |
| % within KRAS overexpression CTC | 78.1% | 21.9% | 100.0% | ||
| % within KRAS CTC | 100.0% | 100.0% | 100.0% | ||
| % of total | 78.1% | 21.9% | 100.0% | ||